We Bring Top Biotech Executives Together to do the Deal

For twenty-five years Daedalus has given its clients a competitive edge in orphan drug acquisition.

A biopharma with impressive management, plenty of cash, and Nobel-level science can still fail, while a single successful compound can ensure a firm’s future.

There are near 100 commercially-sized orphan diseases, including lysosomal storage and metabolic, endocrine, and neurodegenerative without a single approved drug or compound in clinical development.

Orphan Drug Acquisition Specialists

Helping Biopharmas Succeed in a Promising Orphan Environment

Daedalus’ proprietary database tracks orphan disease opportunities worldwide, identifying the most promising approved drugs and compounds in development available for acquisition, licensing, and partnership.

With unexcelled industry and academic coverage, twenty-five years experience, the support of leading scientists and clinicians, and a comprehensive database of orphan assets from both biopharma and academic sources, Daedalus gives its clients a formidable competitive advantage.

Learn more


Orphan asset licensing: acquisition, partnering, and sale. Biopharmas that rely on inlicensing to fill their pipelines are at an increasing disadvantage competing against major firms with growing appetites for orphan drugs. Success in acquiring the most attractive orphan assets requires mastery of a market with over 40,000 compounds, 10,000 disorders, and hundreds of competitors. Daedalus has that mastery.

Learn more

Business Development

Information acquisition is the most productive use of drug development dollars. No firm will ever fail for being too thorough in building its pipeline.

Daedalus’ unique mastery command of the orphan drug market ensures its clients an early look at the most desirable assets and emerging therapeutic opportunities.

Learn more

Contract Research

Leading scientists and clinicians from universities, research institutes, and teaching hospitals covering every rare disease group are available for client-directed research.

Particular emphasis lately is on small molecule therapies for lysosomal storage diseases and protein misfolding and aggregation disorders.

(see list of recent projects)